Low-density lipoprotein receptor-related protein 1 (LRP1), also known as CD91, is a multifunctional 600 kDa Type I transmembrane receptor. Composed of a 515 kDa extracellular alpha-chain and an 85 kDa transmembrane beta-chain, LRP1 mediates the endocytosis of over 40 distinct ligands. In modern biotherapeutics, LRP1 has emerged as a premier target for Receptor-Mediated Transcytosis (RMT) to deliver therapeutics across the Blood-Brain Barrier (BBB), as well as a key player in oncology, neurodegeneration (Alzheimer's disease), and clearance of amyloid-beta.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LRP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRP1 Cluster II / Cluster IV Recombinant Protein HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled (<1 EU/µg), Sequence Verified. Focuses on the primary ligand-binding domains. |
View LRP1 Products |
| Gene Delivery | LRP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based transcytosis and binding assays. |
View LRP1 Products |
| Benchmark Ab | Anti-LRP1 Recombinant Antibody Recombinant positive control derived from benchmark sequences for binding and internalization validation. |
View LRP1 Products |
| Validator | LRP1 siRNA Set Target-specific knockdown pool for specificity and functional pathway validation. |
View LRP1 Products |
| Related Target A | TFRC (Transferrin Receptor) Alternative major RMT pathway target for blood-brain barrier drug delivery comparison. |
View TFRC Products |
| Related Target B | LDLR (Low-Density Lipoprotein Receptor) Homologous family member used to assess off-target binding and selectivity. |
View LDLR Products |
| Related Target C | LRP2 (Megalin) Subfamily member sharing ligand-binding structural motifs; essential for counter-screening. |
View LRP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Expression of 600 kDa full-length protein | Domain-specific strategy: Recombinant LRP1 Cluster II and Cluster IV domain proteins expressed in HEK293 for native disulfide folding. |
| Subfamily cross-reactivity (LDLR/LRP2) | Homolog panel proteins strictly verified by mass spectrometry and theoretical MW comparison. |
| Lack of Controls for Transcytosis | Sequence-verified clinical benchmark antibodies available as reference controls. |
| False Positives in Binding Assays | Validated siRNA included for target knockdown and specificity verification. |
Live LRP1/CD91 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The development of therapeutics targeting LRP1 is rapidly expanding, with major pharmaceutical players shifting focus from traditional clearance mechanisms to utilizing LRP1 as an active carrier for central nervous system (CNS) drug delivery. By leveraging receptor-mediated transcytosis, bioconjugates (peptides, antibodies, and nanoparticles) can cross the blood-brain barrier efficiently. As first-generation RMT platforms enter advanced clinical phases, the next wave of R&D is targeting pH-sensitive, low-affinity LRP1 binders that release their therapeutic cargo seamlessly upon crossing into the brain parenchyma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide-Drug Conjugates (PDCs) | Angiochem, Biogen | Brain Metastases, Glioma, Lysosomal Storage Diseases | In vitro transcytosis assays requiring LRP1 Lentivirus-driven stable cell lines. |
| Bispecific Antibodies (RMT Shuttle) | Denali Therapeutics, Roche | Alzheimer's Disease, Parkinson's Disease | pH-dependent binding assays requiring high-purity LRP1 Cluster II/IV proteins. |
| Monoclonal Antibodies / Inhibitors | Academic Consortia, Oncology Biotechs | Advanced Solid Tumors, Neuroinflammation | Selectivity screening using LRP1, LDLR, and LRP2 recombinant panels. |